Pfizer CEO Albert Bourla effectively closed the door Tuesday on knowing whether or not its experimental coronavirus vaccine would work by the end of October.
On the New York pharma giant’s third quarter earnings call, Bourla acknowledged the company has not yet started the first interim analysis for this final study, called a phase-three trial.
In September, Bourla set public expectations for an October data readout, a timeline at odds with top government scientists like Dr. Anthony Fauci and Moncef Slaoui, Operation Warp Speed’s chief scientist.
Pharmaceutical company Eli Lilly announced Monday it would stop trials testing an antibody drug in hospitalized patients after data suggested treatment was "unlikely" to help this group recover from COVID-19.
Eli Lilly had paused trials of the treatment in mid October after an independent board of experts raised health concerns.
